Back to Search Start Over

02.09 Identification of a novel pro-inflammatory T cell epitope from his-trna-synthetase associated with interstitial lung disease in anti-jo-1 positive patients

Authors :
Maryam Dastmalchi
Antonella Notarnicola
Vivianne Malmström
Ingrid E. Lundberg
Inka Albrecht
Genadiy Kozhukh
Adnane Achour
Anatoly Dubnovitsky
Tatiana Sandalova
Angeles Shunashy Galindo-Feria
Lars Rönnblom
Source :
New players and novel targets in inflammation.
Publication Year :
2017
Publisher :
BMJ Publishing Group Ltd and European League Against Rheumatism, 2017.

Abstract

Background Previous studies have demonstrated that CD4+ T cells from peripheral blood of anti-histidyl-tRNA synthetase (anti-His-tRNA) also known as anti-Jo-1 positive patients proliferate in response to stimulation with full-length His-tRNA and a N-terminal fragment comprising residues 1–60. In this study we present a novel epitope that identifies patients with moderate-severe interstitial lung disease (ILD). Materials and Methods Sixteen anti-Jo-1 positive patients with antisynthetase syndrome followed at the Karolinska University Hospital were enrolled. As controls we included HLA-DRB1*03-positive healthy individual (HCs, n=8). Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque density centrifugation and in vitro stimulated with: a) full length His-tRNA protein; b) a novel HLA-DR*03:01 binding peptide from native His-tRNA; c) an altered peptide ligand (APL) variant of His-tRNA designed to prevent recognition by HLA-DR3/His-tRNA-specific TCRs. T cell activation was assessed by CD40L up-regulation and expression of pro-inflammatory cytokines (IFN-g, IL-2 and IL-17A) by flow cytometry. Clinical and laboratory data were documented and analysed by Student’s T test or Mann-Withney U-test. Results At the time of blood sampling the patients had a mean age of 58 years (48–83 years), median disease duration of 50 months (11–70 months), MMT8 score 80 (79-80), HAQ 0.25 (0 13-0.75). Eighty-four percent were female, 13/16 patients had ILD and 13/16 had muscle weakness. T cell activation towards the novel His-tRNA peptide was observed in 2/16 anti-Jo-1 positive patients. When stimulating with the APL, no T cell activation was observed in one of the patients that was reactive for the peptide. For evaluation of pro-inflammatory features, the His-tRNA-specific T cells displayed significant up-regulated levels of IFN-γ (p Conclusion In this study, we demonstrate the presence of His-tRNA-reactive CD4+ T cells in peripheral blood from anti-Jo-1 positive patients and a novel His-tRNA peptide, characterised by the expression of IFN-g. This phenotype seemed to correlate to a moderate-severe clinical progression of ILD.

Details

Database :
OpenAIRE
Journal :
New players and novel targets in inflammation
Accession number :
edsair.doi...........8d9a55dc9bf7d66298fc741e15c319bd
Full Text :
https://doi.org/10.1136/annrheumdis-2016-211050.9